(Press-News.org) Contact information: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Lou Gehrig's disease: From patient stem cells to potential treatment strategy in one study
Translational research goes seamless: After creating neurons from patients' skin cells, cedars-sinai-led researchers 'treat' gene defect in a dish, indicating the therapy may work
LOS ANGELES (Oct. 25, 2013) – Although the technology has existed for just a few years, scientists increasingly use "disease in a dish" models to study genetic, molecular and cellular defects. But a team of doctors and scientists led by researchers at the Cedars-Sinai Regenerative Medicine Institute went further in a study of Lou Gehrig's disease, a fatal disorder that attacks muscle-controlling nerve cells in the brain and spinal cord.
After using an innovative stem cell technique to create neurons in a lab dish from skin scrapings of patients who have the disorder, the researchers inserted molecules made of small stretches of genetic material, blocking the damaging effects of a defective gene and, in the process, providing "proof of concept" for a new therapeutic strategy – an important step in moving research findings into clinical trials.
The study, published Oct. 23 in Science Translational Medicine, is believed to be one of the first in which a specific form of Lou Gehrig's disease, or amyotrophic lateral sclerosis, was replicated in a dish, analyzed and "treated," suggesting a potential future therapy all in a single study.
"In a sense, this represents the full spectrum of what we are trying to accomplish with patient-based stem cell modeling. It gives researchers the opportunity to conduct extensive studies of a disease's genetic and molecular makeup and develop potential treatments in the laboratory before translating them into patient trials," said Robert H. Baloh, MD, PhD, director of Cedars-Sinai's Neuromuscular Division in the Department of Neurology and director of the multidisciplinary ALS Program. He is the lead researcher and the article's senior author.
Laboratory models of diseases have been made possible by a recently invented process using induced pluripotent stem cells – cells derived from a patient's own skin samples and "sent back in time" through genetic manipulation to an embryonic state. From there, they can be made into any cell of the human body.
The cells used in the study were produced by the Induced Pluripotent Stem Cell Core Facility of Cedars-Sinai's Regenerative Medicine Institute. Dhruv Sareen, PhD, director of the iPSC facility and a faculty research scientist with the Department of Biomedical Sciences, is the article's first author and one of several institute researchers who participated in the study.
"In these studies, we turned skin cells of patients who have ALS into motor neurons that retained the genetic defects of the disease," Baloh said. "We focused on a gene, C9ORF72, that two years ago was found to be the most common cause of familial ALS and frontotemporal lobar degeneration, and even causes some cases of Alzheimer's and Parkinson's disease. What we needed to know, however, was how the defect triggered the disease so we could find a way to treat it."
Frontotemporal lobar degeneration is a brain disorder that typically leads to dementia and sometimes occurs in tandem with ALS.
The researchers found that the genetic defect of C9ORF72 may cause disease because it changes the structure of RNA coming from the gene, creating an abnormal buildup of a repeated set of nucleotides, the basic components of RNA.
"We think this buildup of thousands of copies of the repeated sequence GGGGCC in the nucleus of patients' cells may become "toxic" by altering the normal behavior of other genes in motor neurons," Baloh said. "Because our studies supported the toxic RNA mechanism theory, we used two small segments of genetic material called antisense oligonucleotides – ASOs – to block the buildup and degrade the toxic RNA. One ASO knocked down overall C9ORF72 levels. The other knocked down the toxic RNA coming from the gene without suppressing overall gene expression levels. The absence of such potentially toxic RNA, and no evidence of detrimental effect on the motor neurons, provides a strong basis for using this strategy to treat patients suffering from these diseases."
Researchers from another institution recently led a phase one trial of a similar ASO strategy to treat ALS caused by a different genetic mutation and reportedly uncovered no safety issues.
Clive Svendsen, PhD, director of the Regenerative Medicine Institute and one of the article's authors, has studied ALS for more than a decade. "ALS may be the cruelest, most severe neurological disease, but I believe the stem cell approach used in this collaborative effort holds the key to unlocking the mysteries of this and other devastating disorders. Within the Regenerative Medicine Institute, we are exploring several other stem cell-based strategies in search of treatments and cures," he said, adding that ALS affects 30,000 to 50,000 people in the U.S., but unlike other neurodegenerative diseases, it is almost always fatal, usually within three to five years.
Svendsen recently received a $17.8 million grant from the California Institute for Regenerative Medicine. In collaboration with Baloh and the ALS clinical team at Cedars-Sinai, this study will support a novel stem cell and growth factor therapy for ALS.
###
Researchers from UCLA; the Mayo Clinic in Jacksonville, Fla.; the University of California, San Diego; Washington University School of Medicine in St. Louis, Mo.; and Isis Pharmaceuticals contributed to the C9ORF72 study.
The research was supported by National Institutes of Health grants NS055980, NS069669, NIH-U24NS07837; and California Institute of Regenerative Medicine grant RT2-02040. Baloh holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. Analytical work was partially supported by the UCLA Muscular Dystrophy Core Center funded by the National Institute of Arthritis, Musculoskeletal and Skin Disorders (P30 AR057230) within the Center for Duchenne Muscular Dystrophy at UCLA.
Citation: Science Translational Medicine, "Targeting RNA foci reduces pathology in iPSC-derived motor neurons from C9ORF72 repeat patients."
Lou Gehrig's disease: From patient stem cells to potential treatment strategy in one study
Translational research goes seamless: After creating neurons from patients' skin cells, cedars-sinai-led researchers 'treat' gene defect in a dish, indicating the therapy may work
2013-10-25
ELSE PRESS RELEASES FROM THIS DATE:
Recognizing cancer diseases at an early stage
2013-10-25
Recognizing cancer diseases at an early stage
RUB researchers develop label-free automatic cancer diagnostics
Researchers at the Ruhr-Universität Bochum (RUB) have developed a new spectroscopic method to support pathologists in diagnosing cancer. In the ...
Salvianolate for treatment of cerebral ischemia-reperfusion injuries
2013-10-25
Salvianolate for treatment of cerebral ischemia-reperfusion injuries
Salvianolic acid B, also called salvia magnesium acetate, is a phenolic acid compound composed of three Danshensu units and one molecule of caffeic acid. Salvianolic acid B exerts strong resistance ...
Loss and damage from climate change
2013-10-25
Loss and damage from climate change
Despite attempts at adaption losses and damage from climate change are significant
An open access special issue of the International Journal of Global Warming brings together, for the first time, empirical evidence of loss and damage from ...
What determines which sources within an episode are successfully remembered?
2013-10-25
What determines which sources within an episode are successfully remembered?
Memory about a core item (such as a word, object, or picture) is called item memory while memory about the context or related features of a core item is defined as source memory. What determines ...
How does ursolic acid induce neural regeneration after sciatic nerve injury?
2013-10-25
How does ursolic acid induce neural regeneration after sciatic nerve injury?
Ursolic acid (chemical name 3-hydroxy-12- ursen-28-oic acid) is a triterpenoid extracted from natural plant-based drugs, and has anti-oxidative, anti-inflammatory, anti-apoptotic, and anti-scarring ...
Hope of new treatment for severe asthma patients
2013-10-25
Hope of new treatment for severe asthma patients
New research from Japan brings hope of a new treatment for asthma patients resistant to corticosteroids. In a study published today in the journal Nature Communications, researchers from the RIKEN Center for Integrative Medical Sciences ...
An antibody fragment designed at the UAB ameliorates first hallmarks of Alzheimer's disease in mice
2013-10-25
An antibody fragment designed at the UAB ameliorates first hallmarks of Alzheimer's disease in mice
Researchers at the Biosciences Unit of the Department of Biochemistry and Molecular Biology at the Universitat Autònoma de Barcelona (UAB), in ...
Important step towards stem cell-based treatment for stroke
2013-10-25
Important step towards stem cell-based treatment for stroke
Brain infarction or stroke is caused by a blood clot blocking a blood vessel in the brain, which leads to interruption of blood flow and shortage of oxygen. Now a reserach group at Lund University, Sweden, has ...
Scientists' new approach improves efficiency of solar cells
2013-10-25
Scientists' new approach improves efficiency of solar cells
An international team of scientists, led by researchers from the Universities of York and St Andrews, has developed a new method to increase the efficiency of solar cells.
The new approach achieves highly ...
Saarbrücken physicists aim to make transition to quantum world visible
2013-10-25
Saarbrücken physicists aim to make transition to quantum world visible
This news release is available in German. Theoretical physicist Frank Wilhelm-Mauch and his research team at Saarland University have developed a mathematical model for a ...
LAST 30 PRESS RELEASES:
Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid
Low LDL cholesterol levels linked to reduced risk of dementia
Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients
Almost one in ten people surveyed report having been harmed by the NHS in the last three years
Enhancing light control with complex frequency excitations
New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients
New insight into factors associated with a common disease among dogs and humans
Illuminating single atoms for sustainable propylene production
New study finds Rocky Mountain snow contamination
Study examines lactation in critically ill patients
UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award
Doubling down on metasurfaces
New Cedars-Sinai study shows how specialized diet can improve gut disorders
Making moves and hitting the breaks: Owl journeys surprise researchers in western Montana
PKU Scientists simulate the origin and evolution of the North Atlantic Oscillation
ICRAFT breakthrough: Unlocking A20’s dual role in cancer immunotherapy
How VR technology is changing the game for Alzheimer’s disease
A borrowed bacterial gene allowed some marine diatoms to live on a seaweed diet
Balance between two competing nerve proteins deters symptoms of autism in mice
Use of antifungals in agriculture may increase resistance in an infectious yeast
Awareness grows of cancer risk from alcohol consumption, survey finds
The experts that can outsmart optical illusions
Pregnancy may reduce long COVID risk
Scientists uncover novel immune mechanism in wheat tandem kinase
Three University of Virginia Engineering faculty elected as AAAS Fellows
Unintentional drug overdoses take a toll across the U.S. unequally, study finds
A step toward plant-based gelatin
ECMWF unveils groundbreaking ML tool for enhanced fire prediction
The food and fuel that farms itself
Patient- and Community-Level Characteristics Associated With RSV Vaccination
[Press-News.org] Lou Gehrig's disease: From patient stem cells to potential treatment strategy in one studyTranslational research goes seamless: After creating neurons from patients' skin cells, cedars-sinai-led researchers 'treat' gene defect in a dish, indicating the therapy may work